Valneva Projects Significant Sales Growth by 2026

French biotech company Valneva released encouraging projections for increased product sales by 2026.  The company anticipates nearly doubling annual sales, largely fuelled by the growth of its travel vaccines (Ixiaro and Dukoral) and the recent launch of Ixchiq, the first-ever chikungunya vaccine.

Guidance and Outlook

Valneva revised its 2024 revenue guidance slightly upward to €170-190 million, focusing on product sales in the €160-180 million range. Ixiaro is expected to maintain double-digit growth for at least three years. Additionally, while third-party sales may see short-term declines due to the end of a collaboration, the overall impact on product sales is expected to be minimal by 2026-2027.